Midway through trading Wednesday, the Dow traded down 0.37% to 30,061.07 while the NASDAQ fell 0.28% to 12,546.99. The S&P also fell, dropping 0.28% to 3,691.99.
The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 15,172,600 cases with around 286,330 deaths. India confirmed a total of at least 9,735,850 confirmed cases and 141,360 deaths, while Brazil reported over 6,674,990 COVID-19 cases with 178,150 deaths. In total, there were at least 68,321,800 cases of COVID-19 worldwide with over 1,559,700 deaths, according to data compiled by Johns Hopkins University.
Leading and Lagging Sectors
Consumer discretionary shares climbed 0.3% on Wednesday. Meanwhile, top gainers in the sector included Liquidity Services, Inc. LQDT, up 15%, and Stitch Fix, Inc. SFIX, up 14%.
In trading on Wednesday, real estate shares fell 1.3%.
Top Headline
Campbell Soup Company CPB reported stronger-than-expected earnings for its first quarter, but issued weak guidance for the second quarter.
Campbell Soup reported quarterly earnings of $1.02 per share, beating analysts’ estimates of $0.91 per share. The company’s sales came in at $2.34 billion, versus expectations of $2.32 billion. The company also raised its quarterly dividend from $0.35 to $0.37 per share.
Campbell Soup said it expects Q2 adjusted earnings of $0.81 to $0.83 per share on sales growth of 5% to 7% year over year.
Equities Trading UP
Greenwich LifeSciences, Inc. GLSI shares shot up 227% to $16.98 after the company announced a poster presentation of five-year data for its GP2 Phase IIb clinical trial. The company reported data showing 0% breast cancer recurrences following surgery and Herceptin treatment over median 5 years of follow-up.
Shares of Rocket Pharmaceuticals, Inc. RCKT got a boost, shooting 75% to $56.00 after the company announced preliminary data from its open-label, Phase 1 clinical trial of its AAV-based gene therapy candidate RP-A501 for the treatment of Danon Disease, showing the gene therapy was generally well tolerated and provided early evidence of clinical benefit. The company also announced a $175 million public offering of common stock.
Intec Pharma Ltd NTEC shares were also up, gaining 60% to $5.54 after the company announced a cannabinoid research collaboration with GW Pharma.
Equities Trading DOWN
Pluristem Therapeutics Inc. PSTI shares tumbled 37% to $7.22 after the company said following interim review of dataset from the pivotal Phase 3 study of PLX-PAD in critical limb ischemia, the independent Data Monitoring Committee said the study is unlikely to meet the primary endpoint by the time of the final analysis.
Shares of Sino-Global Shipping America, Ltd.. SINO were down 38% to $2.39 after the company reported pricing of $4.8 million registered direct offering priced at-the-market.
Atossa Therapeutics, Inc. ATOS was down, falling 39% to $0.8690 after the company reported pricing of $20.0 million underwritten public offering.
Commodities
In commodity news, oil traded down 1% to $45.13, while gold traded down 1.3% to $1,850.20.
Silver traded down 2% Wednesday to $24.235 while copper rose 0.2% to $3.5075.
Euro zone
European shares were mostly higher today. The eurozone’s STOXX 600 rose 0.45%, the Spanish Ibex Index rose 0.2%, while Italy’s FTSE MIB Index rose 0.03%. Meanwhile, the German DAX 30 gained 0.68%, French CAC 40 fell 0.11% and London’s FTSE 100 rose 0.28%.
The eurozone GDP rose 12.5% quarter-over-quarter during the third quarter, but declined 4.3% year-over-year. Spain's industrial production declined 1.6% year-over-year in October. German trade balance surplus increased to €18.2 billion in October.
Economics
The number of job openings rose by 158,000 to 6.652 million in October.
US wholesale inventories increased 1.1% for October.
US crude oil supplies gained 15.19 million barrel last week, the Energy Information Administration reported.
The Treasury will auction 10-year notes at 1:00 p.m. ET.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.